Evolution and phenotypic characterization of whole HBV genome in compliant patients experiencing unexplained entecavir treatment failure.

[1]  X. Causse,et al.  Revisiting HBV resistance to entecavir with a phenotypic approach. , 2020, Antiviral research.

[2]  M. Buti,et al.  Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. , 2020, Journal of hepatology.

[3]  S. Chow,et al.  Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis , 2020, Hepatology International.

[4]  F. Zoulim,et al.  Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. , 2019, Journal of hepatology.

[5]  F. Zoulim,et al.  Therapeutic strategies for hepatitis B virus infection: towards a cure , 2019, Nature Reviews Drug Discovery.

[6]  M. Buti,et al.  Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients , 2019, Scientific Reports.

[7]  S. Taghavi,et al.  Comparison of pre-S1/S2 variations of hepatitis B virus between asymptomatic carriers and cirrhotic/hepatocellular carcinoma-affected individuals , 2019, Clinical and experimental hepatology.

[8]  P. Vanhems,et al.  Perinatal hepatitis B virus transmission in Lao PDR: A prospective cohort study , 2019, PloS one.

[9]  Dan Luo,et al.  Prevalence of the entecavir‐resistance‐inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients , 2019, Antiviral research.

[10]  F. Zoulim,et al.  Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice , 2019, Emerging microbes & infections.

[11]  J. Pawlotsky,et al.  Primary resistance of hepatitis B virus to nucleoside and nucleotide analogues , 2018, Journal of viral hepatitis.

[12]  P. Falk,et al.  Discovery of the Novel Entecavir‐Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis , 2018, Hepatology communications.

[13]  D. Cui,et al.  Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg , 2018, International journal of molecular medicine.

[14]  M. Poljak,et al.  Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe , 2018, BMC Infectious Diseases.

[15]  D. Corti,et al.  Viral envelope-specific antibodies in chronic hepatitis B virus infection. , 2018, Current opinion in virology.

[16]  S. Alavian,et al.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.

[17]  G. Lee,et al.  Pyrosequencing method for sensitive detection of HBV drug resistance mutations , 2018, Journal of medical virology.

[18]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[19]  T. Liang,et al.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. , 2017, Gastroenterology.

[20]  H. Zhuang,et al.  The nucleotide changes within HBV core promoter/precore during the first 12weeks of nucleos(t)ide treatment might be associated with a better virological response. , 2017, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[21]  A. Moreau,et al.  Deep sequencing is an appropriate tool for the selection of unique Hepatitis C virus (HCV) variants after single genomic amplification , 2017, PloS one.

[22]  M. Sanou,et al.  Molecular characterization of hepatitis B virus in blood donors from Burkina Faso: Prevalence of quasi‐subgenotype A3, genotype E, and mixed infections , 2016, Journal of medical virology.

[23]  E. Sagnelli,et al.  Clinical significance of hepatitis B surface antigen mutants. , 2015, World journal of hepatology.

[24]  T. Mazzulli,et al.  Implementation of Next-Generation Sequencing for Hepatitis B Virus Resistance Testing and Genotyping in a Clinical Microbiology Laboratory , 2015, Journal of Clinical Microbiology.

[25]  Hong Tang,et al.  Biological characteristics of the A1762T/G1764A mutant strain of hepatitis B virus in vivo. , 2015, Molecular medicine reports.

[26]  Jiming Zhang,et al.  Partial virological response to entecavir treatment in nucleos(t)ide-naïve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity. , 2015, Biochemical and biophysical research communications.

[27]  Y. Karino,et al.  Characterization of novel entecavir resistance mutations. , 2015, Journal of hepatology.

[28]  S. Qin,et al.  Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. , 2015, World journal of gastroenterology.

[29]  Y. Cha,et al.  Prolonged Entecavir Therapy Is Not Effective for HBeAg Seroconversion in Treatment-Naive Chronic Hepatitis B Patients with a Partial Virological Response , 2015, Antimicrobial Agents and Chemotherapy.

[30]  Y. Louzoun,et al.  Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression , 2015, Hepatology.

[31]  M. Yuen,et al.  Entecavir treatment in kidney transplant recipients infected with hepatitis B , 2014, Clinical transplantation.

[32]  Sheng-Nan Lu,et al.  Antiviral effect of entecavir in nucleos(t)ide analogue‐naïve and nucleos(t)ide analogue‐experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy , 2014, Journal of viral hepatitis.

[33]  I. Lazarević.  Clinical implications of hepatitis B virus mutations: recent advances. , 2014, World journal of gastroenterology.

[34]  Mengji Lu,et al.  Spontaneous reactivation of hepatitis B virus replication in an HIV coinfected patient with isolated anti-Hepatitis B core antibodies , 2014, Virology Journal.

[35]  Chun-Jen Liu,et al.  Impact of Genetic Heterogeneity in Polymerase of Hepatitis B Virus on Dynamics of Viral Load and Hepatitis B Progression , 2013, PloS one.

[36]  W. Gerlich,et al.  Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti‐HBc negative patient , 2013, Journal of medical virology.

[37]  F. Zoulim,et al.  Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[38]  Alan Kay,et al.  HBVdb: a knowledge database for Hepatitis B Virus , 2012, Nucleic Acids Res..

[39]  Hee-Young Kim,et al.  C-Terminal Substitution of HBV Core Proteins with Those from DHBV Reveals That Arginine-Rich 167RRRSQSPRR175 Domain Is Critical for HBV Replication , 2012, PloS one.

[40]  M. Buti,et al.  Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response , 2011, Hepatology.

[41]  W. Stremmel,et al.  Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. , 2010, World journal of gastroenterology.

[42]  D. Muljono,et al.  Prediction of conformational changes by single mutation in the hepatitis B virus surface antigen (HBsAg) identified in HBsAg-negative blood donors , 2010, Virology Journal.

[43]  F. Le Gal,et al.  A novel hepatitis B virus (HBV) subgenotype D (D8) strain, resulting from recombination between genotypes D and E, is circulating in Niger along with HBV/E strains. , 2010, The Journal of general virology.

[44]  T. Luedde,et al.  Differential Impact of Immune Escape Mutations G145R and P120T on the Replication of Lamivudine-Resistant Hepatitis B Virus e Antigen-Positive and -Negative Strains , 2009, Journal of Virology.

[45]  Ronald E. Rose,et al.  Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy , 2009, Hepatology.

[46]  J. Hübschen,et al.  Possible New Hepatitis B Virus Genotype, Southeast Asia , 2008, Emerging infectious diseases.

[47]  K. Abe,et al.  New Complex Recombinant Genotype of Hepatitis B Virus Identified in Vietnam , 2008, Journal of Virology.

[48]  F. Zoulim,et al.  Hepatitis B virus genetic variability and evolution. , 2007, Virus research.

[49]  Angeline Bartholomeusz,et al.  Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management , 2007, Hepatology.

[50]  M. Purdy,et al.  A New Algorithm for Deduction of Hepatitis B Surface Antigen Subtype Determinants from the Amino Acid Sequence , 2006, Intervirology.

[51]  A. Pajot,et al.  Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects. , 2006, Microbes and infection.

[52]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.

[53]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[54]  B. Rehermann,et al.  Immunology of hepatitis B virus and hepatitis C virus infection , 2005, Nature Reviews Immunology.

[55]  B. Weber.  Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. , 2005 .

[56]  F. Fack,et al.  Low genetic diversity despite hyperendemicity of hepatitis B virus genotype E throughout West Africa. , 2004, The Journal of infectious diseases.

[57]  C. Gibbs,et al.  Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. , 2003, Journal of hepatology.

[58]  B. Seong,et al.  Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy , 2003, Journal of medical virology.

[59]  F. Zoulim,et al.  Genome Replication, Virion Secretion, and e Antigen Expression of Naturally Occurring Hepatitis B Virus Core Promoter Mutants , 2003, Journal of Virology.

[60]  M. Manns,et al.  Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. , 2002, Gastroenterology.

[61]  H. Lei,et al.  Prevalence and significance of hepatitis B virus (HBV) pre‐S mutants in serum and liver at different replicative stages of chronic HBV infection , 2001, Hepatology.

[62]  C. Hannoun,et al.  An aberrant genotype revealed in recombinant hepatitis B virus strains from Vietnam. , 2000, The Journal of general virology.

[63]  C. Guguen-Guillouzo,et al.  Role of the Pre-S2 Domain of the Large Envelope Protein in Hepatitis B Virus Assembly and Infectivity , 1998, Journal of Virology.

[64]  S. Günther,et al.  A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients , 1995, Journal of virology.

[65]  V. Barnaba,et al.  Recognition of hepatitis B virus envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection. , 1989, Journal of immunology.